Patients with epilepsy often have mood disorders, and these are commonly treated with antidepressant drugs. Although these drugs are often successful in mitigating depressive symptoms, how they affect the epileptogenic processes has been little studied. Recent evidence has demonstrated that treatment with selective serotonin reuptake inhibitor (SSRI) antidepressant drugs adversely promotes epileptogenesis, which may be of great concern considering the number of patients exposed to these drugs. This study investigated 5-HT 2A receptor signaling as a potential mechanism driving the pro-epileptogenic effects of the prototypical SSRI fluoxetine. Male homozygous 5-HT 2A receptor knockout mice or wild-type littermates (n = 9-14/group) were treated with continuous fluoxetine (10 mg kg À1 d À1 , sc) or vehicle and subjected to electrical kindling of the amygdala. Compared to vehicle, fluoxetine treatment accelerated kindling epileptogenesis (P < .001), but there was no effect of genotype (P = .75), or any treatment x genotype interaction observed (P = .90). Of interest, fluoxetine treatment increased afterdischarge thresholds in both genotypes (P = .007). We conclude that treatment with fluoxetine promotes epileptogenesis in mice, but this effect is not mediated by 5-HT 2A receptors. This suggests that antidepressants may accelerate the onset of acquired epilepsy in patients who have experienced epileptogenic cerebral insults.
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| INTRODUCTION
It is now well-recognized that patients with epilepsy are at greater risk of experiencing psychiatric comorbidities than the general population, including depression, anxiety, and suicidality. 1 These comorbidities contribute substantially to reduced quality of life, 2 and can predict poorer seizure outcomes. 3 It is also now apparent that bidirectional relationships exist between these disorders, such that the psychiatric conditions often predate the onset of epilepsy by several years. 4 As such, appropriate diagnoses and adequate management of these comorbidities is now high priority. Newer-generation antidepressant drugs, such as the selective serotonin reuptake inhibitors (SSRIs), constitute the primary pharmacological therapy for depressive disorders.
A wealth of experimental and clinical evidence reports that SSRIs do not aggravate seizures in established, chronic epilepsy at therapeutic doses. 5, 6 However, an important aspect that remains largely unexplored is how SSRIs influence epileptogenesis-the transformation of a regular brain state into one susceptible to generating epileptic activity. This may be important, since many patients at risk of developing epilepsy are treated with antidepressants prior to epilepsy onset, at a time when epileptogenesis is occurring. For example, psychiatric conditions often predate epilepsy onset, 4 inferring that patients may also be exposed to antidepressant drugs prior to epilepsy onset. In addition, brain insults recognized to promote epilepsy, such as traumatic brain injury or stroke, are commonly associated with mood disorders, 7 and would likely require therapeutic intervention. In addition, although great progress is being made in our understanding of the molecular mechanisms underpinning epileptogenesis, these largely remain mysterious, but there are several reasons that exposure to antidepressants may interact with epileptogenic processes. 6 For example, neuroplasticity of limbic circuits-strongly implicated in antidepressant actions-is a central component of most theories explaining epileptogenesis.
In light of this, we previously examined the influence of SSRI antidepressants on epileptogenesis. Using two different compounds-fluoxetine and citalopram-we found that continuous exposure to SSRIs accelerated kindling epileptogenesis. 8 This was the first study to examine this and has triggered a range of subsequent clinical and preclinical investigations. A critical, yet unanswered question is the biological mechanisms underpinning this pro-epileptogenic effect. SSRI antidepressants act to increase synaptic serotonin levels by selectively blocking the serotonin reuptake sites on presynaptic nerve terminals. This leads to increased activation of serotonin receptors, and, since therapeutic improvement for depression symptoms typically takes a few weeks, is suggestive of some form of neuroplasticity of appropriate neural circuits. On first principles, understanding which serotonin receptor subtypes mediate the previously identified pro-epileptogenic effect of SSRIs would be a great advance to understanding the molecular mechanisms and downstream signaling pathways adopted. One receptor subtype that has received recent attention is the 5-HT 2A receptor subtype. Dysfunction in this receptor has been linked to epilepsy and depression, 9 and stimulation of this receptor accelerates kindling epileptogenesis. 10 5-HT 2A receptors are G-protein-coupled receptors linked to Gq/G11 to mediate excitatory neurotransmission, and they are expressed in highly epileptogenic brain regions such as the amygdala and hippocampus. 11 Furthermore, a large body of research links this receptor subtype to seizure activity. 9 With this in mind, we designed the current study with two aims: first, to attempt to replicate the observation that fluoxetine accelerates epileptogenesis, this time using mice; and second, to investigate the influence of 5-HT 2A receptors in the pro-epileptogenic effect of SSRI antidepressants. To achieve this, we used 5-HT 2A receptor knockout mice and wild-type littermates, and continuous treatment with fluoxetine or vehicle. We chose to explore genetic rather than pharmacological methods of examining 5-HT 2A receptors because the currently available ligands, such as 2,5-Dimethoxy-4-iodoamphetamine (DOI) and ketanserin used in previous studies, 10 can also interact with other 5-HT receptor subtypes, making this a more direct approach. Our hypothesis was that fluoxetine would accelerate kindling epileptogenesis in wild-type mice, but not in 5-HT 2A receptor knockout mice, inferring that the pro-epileptogenic mechanism of action of fluoxetine is through this receptor subtype. 
| METHODS

| Animals
| Surgical implantation of electrodes and minipumps
Male mice aged 11-14 weeks underwent surgical implantation of electrodes as described previously. 13 This included a stimulating bipolar electrode into the left basolateral amygdala. During the same surgery session, an osmotic minipump (Alzet, Cupertino, CA, USA) was implanted subcutaneously beneath the scapula. Pumps were filled with either vehicle (50% dimethyl sulfoxide (DMSO) in sterile saline) or fluoxetine hydrochloride (Biotrend Chemicals, Wangen, Switzerland). Mice were randomly assigned to treatment, leading to 4 experimental groups: wild-type + vehicle (n = 10), wild-type + fluoxetine (n = 9), 5-HT 2A r
The concentration of fluoxetine was tailored to deliver 10 mg kg À1 d À1 to the mice for 30 days. This dose was chosen based on our previous study, 8 which showed that the plasma levels achieved by this regimen match human plasma levels of patients taking fluoxetine. Mice recovered from surgery for 1 week, at which time kindling commenced. Researchers who performed the kindling were blinded to genotype and treatment.
| Electrical amygdala kindling
Kindling was conducted using a twice-daily stimulation protocol, as described previously 13 .
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On the first day, the afterdischarge threshold was determined, defined as the minimum current required to produce a >6 second electrographic seizure. Seizures were stimulated using an Accupulser Pulse Generator/Stimulator (A310, World Precision Instruments, Sarasota, FL, USA) with the following stimulation parameters: 60 Hz, 1 second duration, 1 millisecond biphasic square wave pulse. Electrographic activity was visualized with LabChart software (ADInstruments, Bella Vista, NSW, Australia). Seizure severity was scored according to the Racine scale. At the conclusion of kindling, electrode location was histologically verified. Animals with incorrect positioning of the bipolar electrode were excluded from all analyses.
| Statistical analysis
Afterdischarge thresholds, kindling rates and seizure durations were analyzed using mixed-model analysis of variance (ANOVA) with Bonferroni post hoc tests, where appropriate. The two independent variables in all analyses were genotype and treatment. Data are presented as group mean and error bars represent standard error of the mean (SEM), and statistical significance was set at P < .05.
| RESULTS
| Afterdischarge threshold is increased with fluoxetine treatment, but is not influenced by 5-HT 2A receptors
The afterdischarge threshold was significantly higher in fluoxetine-treated mice than in vehicle-treated mice (F [1, 42] = 8.10, P = .007; Figure 1B ), suggesting that fluoxetine acutely reduces neuronal excitability. However, this measure was not influenced by genotype (F [1, 42] = 1.91, P = .17), and no significant interactions between treatment and genotype were observed (F [1, 42] = 0.47, P = .50).
| Chronic fluoxetine treatment accelerates kindling epileptogenesis independently of 5-HT 2A receptors
Chronic fluoxetine treatment accelerated kindling epileptogenesis when compared to vehicle-treated animals, as evidenced by significantly fewer stimulations required to reach the successive stages of kindling (F [1, 42] = 10.03, P = .003; Figure 2A ). However, we did not observe any effect of genotype on this outcome (F [1, 42] = 0.01, P = .992; Figure 2A) , and there was no interaction between treatment and genotype (F [1, 42] = 0.24, P = .62). In addition, when assessing the average seizure class elicited by successive stimulations, this was also accelerated by fluoxetine treatment (F [1, 42] =5.05, = 0.03; Figure 2B ).
This effect was particularly evident in the early stages of kindling before the ceiling was reached, verified by a significant interaction between treatment and stimulation (F [14, 588] = 4.27, P < .001). Post hoc analyses revealed that fluoxetine treatment accelerated kindling epileptogenesis when compared to vehicle-treated groups in the initial stages of kindling ( Figure 2B ). The absence of 5-HT 2A receptors did not influence the rates of kindling epileptogenesis (F [1, 42] = 0.01, P = .99; Figure 2B ), and no interaction between treatment and genotype (F [1, 42] = 0.13, P = .72) was observed. Neither fluoxetine treatment (F [1, 42] = 0.22, P = .64; Figure 2C ) nor the absence of 5-HT 2A receptors (F [1, 42] = 0.03, P = .87) influenced seizure duration, and no significant interaction between treatment and genotype was observed (F [1, 42] = 1.91, P = .17).
| DISCUSSION
Here we demonstrate the pro-epileptogenic effects of the SSRI antidepressant fluoxetine in mice, consistent with what we have previously identified in rats. 8 In addition, we show that this effect is not mediated by 5-HT 2A receptors. Indeed, the presence of these receptors does not influence kindling rates at all, evidenced by the overlapping kindling curves in 5-HT 2A receptor null and wild-type mice. This finding reinforces the notion that SSRI antidepressant medications may have negative repercussions on the onset and/ or progression of acquired epilepsy in patients, but that the specific serotonin receptor subtype(s) responsible remain undisclosed.
We were motivated to target the 5-HT 2A receptor in this study as a driver of SSRI effects for several reasons: this subtype has been suggested as a potential mediator of pathogenic processes in both depression and epilepsy 9 ; the expression patterns of 5-HT 2A receptors include cortical and limbic regions, and these regions are also likely to be involved in acquired epileptogenesis; and, a previous study demonstrating that activation of this receptor can accelerate epileptogenesis. 10 Although scant evidence links this receptor subtype to the mechanism of action of SSRI antidepressants, this may not be relevant, since the pro-epileptogenic and antidepressant actions of these compounds may be driven via independent mechanisms. Based on this, we anticipated that fluoxetine treatment would facilitate kindling epileptogenesis in wild-type mice, but not in mice lacking 5-HT 2A receptors. However, our study conclusively rules out this receptor as a possible mediator of this property of SSRIs. Another strong candidate receptor subtype that warrants investigation in future studies is the 5-HT 1A receptor, or alternatively the serotonin transporter, since these proteins have also received much attention in epilepsy/depression research. 14 We chose to deliver fluoxetine via continuous infusion in this study to model the typical exposure of human patients in which fluoxetine levels are in steady state throughout the day. This is in contrast to acute injections normally delivered in rodent studies, which are rapidly metabolized, leading to high peaks in blood concentration, and also periods of low or no circulating drug. This strategy introduces a potential confound for interpretation of any observed effects on epileptogenesis, since the drug is circulating when the stimulations are given, and therefore may influence the acute seizure severity, and hence kindling rate. However, in addition to accelerated rates of kindling, we also show here an acute reduction in neuronal excitability of fluoxetine, as measured by the increase in afterdischarge threshold. This paradoxical finding therefore removes any potential confounds of interpretation of the kindling data here due to constantly circulating fluoxetine levels, since we observe pro-epileptogenic effects of fluoxetine, opposite in nature to the heightened threshold to elicit afterdischarges. Of note, this was a different finding from our previous report on the pro-epileptogenic effects of SSRIs, which found no change in afterdischarge threshold in treated rats-it is unclear why this phenotype is not consistent but may be related to species differences. In addition, it should be recognized that, although SSRIs appear to be safe to use in chronic epilepsy, and possibly have anticonvulsant properties (as identified here), this appears to be separate to the pro-epileptogenic effects. Acute effects of seizure sensitivity may be related to innate excitability of seizure circuitry, whereas epileptogenesis involves alterations involving changes to gene expression and the structure and function of neural circuits. 15 Antidepressants are well-placed to influence epileptogenesis, 6 since these are recognized to modulate a range of different aspects of neuroplasticity related to their antidepressant actions, although it should not be assumed that mechanisms that evoke antidepressant activity overlap with the observed pro-epileptogenic actions of SSRIs.
To conclude, here we demonstrate that chronic treatment with the SSRI fluoxetine accelerates kindling epileptogenesis in mice, but that 5-HT 2A receptors are not necessary for these pro-epileptogenic effects. Future studies are required to identify the receptor, and downstream signaling pathways adopted by this drug, and also to establish whether this is a unique feature of SSRIs or represents a common property of all modern antidepressants. Our findings also motivate investigation of this phenomenon in clinical populations.
